Colivelin

Colivelin is a chimeric peptide combining a modified version of Humanin (a small mitochondria-derived peptide with established neuroprotective activity) and ADNF (Activity-Dependent Neurotrophic Factor) at its N-terminus. The fusion produces a single molecule with substantially greater neuroprotective potency than either parent peptide alone — Colivelin protects neurons from amyloid-β toxicity at femtomolar concentrations in vitro, several orders of magnitude lower than the effective concentration of the parent peptides.

Mechanistically, Colivelin activates the STAT3 pro-survival pathway in neurons via Humanin-receptor binding, and additionally engages ADNF-mediated neurotrophic signaling. In animal models of Alzheimer's disease, intracerebroventricular and peripheral administration of Colivelin attenuated learning and memory deficits, reduced neuronal loss in the hippocampus, and protected against amyloid-β-induced cognitive impairment. It has also shown activity in models of amyotrophic lateral sclerosis (ALS) and ischemic stroke.

Despite a compelling preclinical profile, Colivelin has not advanced to clinical trials and remains a research compound. It is sold by some peptide vendors for in vitro and animal research; human safety and efficacy data are essentially absent.

Colivelin was designed by Ikuo Nishimoto's group at Keio University and reported in 2005 as part of their broader research program on Humanin-family neuroprotective peptides. The molecule was specifically engineered as a Humanin variant with the ADNF fragment fused N-terminally to achieve synergistic activation of pro-survival signaling. Subsequent in vivo studies in mouse models of Alzheimer's disease established its activity across multiple delivery routes including intranasal and intraperitoneal administration. Despite over 15 years of preclinical work it has not been advanced to clinical trials.